Celldex Therapeutics Inc (CLDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.26B
Last updated: Nov 17, 2026 at 11:05 AM ET
Celldex Therapeutics Inc (CLDX) Competitors
The companies most similar to Celldex Therapeutics are Xencor (XNCR), Disc Medicine (IRON) and Sellas Life Sciences Group (SLS). By market cap, Celldex Therapeutics ranks 11th of the 13 companies on this page; Disc Medicine (IRON) is the largest at $3.64B.
Peer Comparison
CLDX's revenue growth of -97.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics (CLDX) | $2.26B | N/A | N/A | 0.0% | N/A | -97.0% | 0.00% |
| Xencor Inc (XNCR) | $2.78B | N/A | 13.5x | -58.8% | -17.3% | 454.9% | 0.00% |
| Disc Medicine Inc. (IRON) | $3.64B | N/A | N/A | 0.0% | -40.0% | 0.0% | 0.00% |
| Sellas Life Sciences Group Inc (SLS) | $1.60B | N/A | N/A | 0.0% | N/A | -82.5% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $3.14B | N/A | 5.3x | 3.8% | -0.7% | 22.3% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Celcuity LLC (CELC) | $3.15B | N/A | N/A | 0.0% | -25.2% | 0.0% | 0.00% |
| Vericel Corp Ord (VCEL) | $2.91B | 89.8x | 9.1x | 10.3% | N/A | 26.5% | 0.00% |
| Dyne Therapeutics Inc (DYN) | $3.22B | N/A | N/A | 0.0% | -42.9% | 0.0% | 0.00% |
| MBX Biosciences, Inc. Common Stock (MBX) | $2.78B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Denali Therapeutics Inc (DNLI) | $3.00B | N/A | 159.3x | 0.0% | N/A | -100.0% | 0.00% |
| Replimune Group Inc (REPL) | $2.08B | N/A | N/A | 0.0% | -65.4% | 0.0% | 0.00% |
| Peer median | $2.96B | 178.2x | 11.3x | 0.0% | -29.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Celldex Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Xencor Inc (XNCR) | Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed... | XNCR competitors |
| Disc Medicine Inc. (IRON) | Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development... | IRON competitors |
| Sellas Life Sciences Group Inc (SLS) | SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications... | SLS competitors |
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
| Telix Pharmaceuticals Limited (TLX) | Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic... | |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Celcuity LLC (CELC) | Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. | CELC competitors |
| Vericel Corp Ord (VCEL) | Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures... | VCEL competitors |
| Dyne Therapeutics Inc (DYN) | Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases... | DYN competitors |
| MBX Biosciences, Inc. Common Stock (MBX) | MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment... | MBX competitors |
| Denali Therapeutics Inc (DNLI) | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. | DNLI competitors |
| Replimune Group Inc (REPL) | Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts. | REPL competitors |
Frequently Asked Questions About CLDX
Who are Celldex Therapeutics' main competitors?
The companies most similar to Celldex Therapeutics include Xencor (XNCR), Disc Medicine (IRON), Sellas Life Sciences Group (SLS), Legend Biotech (LEGN) and Telix Pharmaceuticals (TLX), listed from the closest match.
Who is Celldex Therapeutics' biggest competitor?
Disc Medicine (IRON) is the largest of the similar companies at $3.64B; Xencor (XNCR) is the closest match by business profile, size, sector and industry.
How does CLDX stock compare with its competitors?
CLDX's net margin is 0.0% against a peer median of 0.0%.
Which of Celldex Therapeutics' competitors pays a higher dividend?
Celldex Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Celldex Therapeutics bigger than its competitors?
No. Celldex Therapeutics is 11th by market cap among the 13 companies on this page; the largest is Disc Medicine (IRON) at $3.64B.
CLDX pages: Overview, Earnings, Forecast, Financials, Competitors